Radioactive drug targets advanced prostate cancer in new trial

NCT ID NCT04644770

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called JNJ-69086420 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The drug is a radioactive antibody designed to seek out and deliver radiation directly to prostate cancer cells. The main goals are to find a safe dose and see if the drug shows early signs of helping control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Case Western Reserve University

Cleveland, Ohio, 44106, United States
City of Hope

Duarte, California, 91010, United States
East Jefferson General Hospital

Metairie, Louisiana, 70006, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Tulane University Hospital & Clinics

New Orleans, Louisiana, 70112, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Utah Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
XCancer Omaha / Urology Cancer Center

Omaha, Nebraska, 68130, United States

Conditions

Explore the condition pages connected to this study.

ADENOCARCINOMA PROSTATIC NEOPLASMS